NCT06814925 Italian Study of Patients With Lymphoma
| NCT ID | NCT06814925 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2021-12-07 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2021-12-07 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It is an observational, non-interventional, prospective, monocentric study, whose objective is to enroll 1500 patients with lymphoma in 5 years within the Institute of Hematology "Seragnoli".
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to 18 years at enrollment * Diagnosis of lymphoma within 3 months of enrollment * Patients may have been treated, as long as the initial diagnosis of lymphoma is within 3 months of enrollment * Signing of the informed consent form Exclusion Criteria: * none
Contact & Investigator
Pier Luigi Zinzani, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06814925 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06814925 currently recruiting?
Yes, NCT06814925 is actively recruiting participants. Contact the research team at pierluigi.zinzani@unibo.it for enrollment information.
Where is the NCT06814925 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06814925 clinical trial?
NCT06814925 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Pier Luigi Zinzani, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 1,500 participants.